Elos Medtech Interim Report January 1 - June 30, 2022

April – June 2022

• Net sales for the second quarter amounted to SEK 233.1 (181.0) million, an increase of 28.8 percent compared to the same quarter last year. Net sales in local currencies increased by 19.7 percent.
• Operating profit amounted to SEK 37.8 (26.5) million, corresponding to an operating margin of 16.2 (14.7) percent.
• Profit after net financial items amounted to SEK 38.8 (22.8) million. Net financial items were positively affected by exchange rate differences of SEK 3.6 (-0.9) million and totaled SEK 1.1 (-3.7) million.
• Profit after tax amounted to SEK 29.7 (18.4) million.
• Cash flow from operating activities was SEK 26.4 (34.3) million, and SEK -3.8 (24.0) million after investments.
• Earnings per share amounted to SEK 3.68 (2.28).

For further information, please contact:
Jodie Gilmore, CEO and President & Business Unit Director Orthopedics, +1 (901) 830 4552, e-mail: jodie.gilmore@elosmedtech.com
Ewa Linsäter, Group CFO, +46 76-633 32 33, e-mail: ewa.linsater@elosmedtech.com

This disclosure contains information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above on August 18, 2022, at 08:00 (CEST).

For additional information about the Elos Medtech Group, visit www.elosmedtech.com

Tags: